Ratings SK bioscience Co.,Ltd.

Equities

A302440

KR7302440003

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-16 pm EDT			5-day change	1st Jan Change
56,700 ^KRW	-0.53%		-5.34%	-21.25%

Mar. 28	SK Bioscience Signs Deal with Sanofi for Five Vaccine Types	MT
Mar. 07	SK Bioscience Breaks Ground on Manufacturing Facility Expansion for Extending Product Pipeline	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
For the past twelve months, EPS forecast has been revised upwards.
The opinion of analysts covering the stock has improved over the past four months.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
The company's "enterprise value to sales" ratio is among the highest in the world.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
SK BIOSCIENCE CO.,LTD.	-21.25%	3.15B	B-
CSL LIMITED	-5.32%	84.57B	A-
SAMSUNG BIOLOGICS CO.,LTD.	+2.11%	39.93B	A-
BIOGEN INC.	-25.74%	27.93B	B-
UCB	+52.79%	24.21B	A
BIOMARIN PHARMACEUTICAL INC.	-6.17%	17.17B	C
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-31.09%	13.93B	B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-6.58%	12.3B	D+
INCYTE CORPORATION	-16.04%	11.84B	B-
SWEDISH ORPHAN BIOVITRUM AB	-2.55%	7.91B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes